Roche Holding AG (RHHBY) on Monday announced three-year follow-up results from the pivotal phase III STARGLO study evaluating Columvi in combination with gemcitabine and oxaliplatin (GemOx) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
After a median follow-up of 35.1 months, overall survival remained twice as long for patients receiving Columvi plus GemOx compared with MabThera/Rituxan plus GemOx. Roche reported no new safety signals, with the combination's profile consistent with the known safety of the individual medicines.
The results were presented at the 67th American Society of Hematology Annual Meeting in Orlando, Florida.
Columvi is approved as monotherapy in over 60 countries for R/R DLBCL, with combination use approved or under review in more than 35 countries.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.